 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- anti-CD270 antibody therapeutic / JJP Biologics
Anti-HVEM Antibody Checkpoint Inhibitor for Cancer Treatment: Swing around Patient () - Jun 15, 2023 - Abstract #IOSUMMITEUROPE2023IO_SUMMIT_EUROPE_49;
Anti-CD270 antibodies were selected that specifically inhibit the interaction with immune suppressive ligands CD160 and BTLA but do not inhibit the immune-stimulating CD270-LIGHT interaction. This turns CD270 expressing tumors from immune suppressive to immune stimulatory.